We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Protein Discovery May Lead to New Drugs for Malaria

By Biotechdaily staff writers
Posted on 13 May 2003
Having discovered how a protein called DHFR produced by a microscopic parasite protects itself against current malaria drugs, scientists believe they can design a new generation of drugs for malaria that will be effective.

The pyrimethamine family of drugs is among the most effective classes of antimalarial drugs. More...
Pyrimethamine blocks the function of the protein DHFR, produced by a parasite carried by mosquitoes. By using genetic engineering methods and laboratory strains of bacteria to produce large quantities of DHFR, scientists have been able to identify the ways in which DHFR changes to protect itself from the effects of these drugs. They found that the same part of the protein is always changed.

"We can now use this protein structure to design a new generation of drugs that makes it possible to overcome resistant strains of malaria,” said Professor Malcolm Walkinshaw, of the University of Edinburgh's Institute of Cell and Molecular Biology (UK). "This is a real breakthrough. Drug resistance is a major issue for all infectious diseases, not just malaria.” Dr. Walkinshaw led the study along with Professor Yongyuth Yuthavong of the BIOTEC Institute in Bangkok (Thailand).

Malaria claims up to two million lives each year and accounts for the death of one child every 30 seconds in Africa. The study was funded by the Wellcome Trust (London, UK).





Related Links:
Institute of Cell and Molecular Biology
BIOTEC Institute

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
POC Immunoassay Analyzer
Procise DX
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.